Ireland
--:--IST
Latest
Clinical Trials in France / NCT07578194
Starting soon Not applicable

Coercive Control and Intimate Partner Violence

NCT07578194 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-05-30
Last updated
2026-05-26

Condition(s) studied

Coercive Control

Investigational drug(s) / intervention(s)

questionnaire

questionnaire: Participants will complete online questionnaires via the Qualtrics platform at baseline and at 6 months post-enrollment

Study summary

Coercive control (CC) is increasingly recognized as a central component of intimate partner violence (IPV) and a major determinant of victims' health outcomes. While widely integrated into policy and legal frameworks in several countries, CC remains insufficiently explored in the French research context, particularly regarding its clinical and psychopathological dimensions. This gap may limit the identification of victims and the provision of appropriate care.

The present study aims to investigate the association between exposure to coercive control and physical and mental health outcomes among victims of intimate partner violence. By improving the understanding of CC-related health impacts, this research seeks to support better identification of high-risk situations and inform clinical and public health interventions.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women aged 18 years and older, who have experienced an intimate partner relationship involving violence for at least three months (currently in the relationship or separated). * Women identified as victims of intimate partner violence. * Sufficient proficiency in French to complete self-administered questionnaires and participate in interviews. * No objection to participation in the study (non-opposition). * Affiliation with a French social security scheme or eligibility for universal health coverage (Couverture Maladie Universelle, CMU). Exclusion Criteria: * Individuals under legal protection in accordance with the French Public Health Code (Articles L.1121-5 to L.1121-8 and L.1122-1-2), with the exception of pregnant or breastfeeding women. * Cognitive impairment or severe intellectual disability preventing comprehension of the questionnaires. * Severe and unstable psychiatric disorders (e.g., schizophrenia, delusional disorders, acute bipolar disorder).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHI Robert Ballanger Aulnay-sous-Bois Île-de-France Region

More Centre Hospitalier Intercommunal Robert Ballanger trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07578194 on ClinicalTrials.gov ↗ ← All trials in France